Guanfacine for ADHD
Links shared publicly online about this topic
INTUNIV (Guanfacine) drug information from MPR
empr.com — “INTUNIV (Guanfacine) drug information for ADD, ADHD {ADHD} from MPR including side effects, drug interactions, dosing, contraindications and warnings/precautions.” View full resource at empr.com
Most Recently Shared on April 13, 2011 at 4:19 am By:
MPR News: INTUNIV: Indications: approved as adjunctive therapy. Children: adjunctive therapy dosing added. http://bit.ly/dTFdne
News - Guanfacine Plus Stimulants Improves Symptom Management in Children With ADHD: Presented at APA
docguide.com — “Guanfacine Plus Stimulants Improves Symptom Management in Children With ADHD: Presented at APA” View full resource at docguide.com
Most Recently Shared on May 26, 2010 at 12:03 am By:
Peter H Brown Doctor and Psychologist
Guanfacine Plus Stimulants Improves Symptom Management in Children With ADHD ... http://bit.ly/br20Dl #ADHD
Google Sidewiki entry about Intuniv for ADHD: Understanding Tenex, Guanfacine and Alpha 2
google.com — “Some very interesting comments and updates are following the ADHD crew here - some useful points on Intuniv as well as the larger question of specific testing.” View full resource at google.com
Most Recently Shared on January 17, 2010 at 11:15 pm By:
Educator, Writer, Neuroscientist, Child and Adult psychiatrist, and is certified by the Nuclear Regulatory Commission for SPECT brain imaging. He specializes in advanced diagnostic and medical services for troubled children, adolescents and adults. His broad range of clinical experience from psychoanalysis to substance abuse, to psychopharmacology and SPECT neuroimaging, – and his experience with systems/functional medicine and biomedical assessments provides a comprehensive medical foundation for treatment interventions and recommendations. If you don't look, you can't see. At CorePsych mind/brain diagnosis evolves beyond the polemics of outdated categorical thinking driven by superficial labels. Virtual assessments available anywhere globally." /> Dr Charles Parker Active Health Library, Doctor, Psychiatrist, and Physician
Over 100 Comments-Sidewiki entry on "Intuniv for ADHD: Understanding Tenex, Guanfacine and Alpha 2" http://bit.ly/78jSJq
Guanfacine, psychostimulants improved ADHD symptoms in children, adolescents
pediatricsupersite.com — “Guanfacine XR, a selective alpha-2A agonist approved for treating attention-deficit/hyperactivity disorder, significantly improved symptoms in c” View full resource at pediatricsupersite.com
Most Recently Shared on May 28, 2010 at 4:08 am By:
Peter H Brown Doctor and Psychologist
Guanfacine, psychostimulants improved ADHD symptoms in children, adolescents http://bit.ly/bgnxoB #ADHD
Guanfacine extended release for ADHD — Current Psychiatry Online
currentpsychiatry.com — “Guanfacine extended release for ADHD — Current Psychiatry Online” View full resource at currentpsychiatry.com
Most Recently Shared on January 21, 2010 at 3:24 pm By:
Current Psychiatry Psychiatry and Medical Journal
Guanfacine extended release for #ADHD: Once-daily formulation may improve adherence, control symptoms across a full day http://bit.ly/6SNmRn
FDA approves guanfacine ER tablets to treat ADHD in children, teens - - Drug Topics
drugtopics.modernmedicine.com — “FDA approved the use of once-daily guanfacine (Intuniv, Shire) extended-release tablets as adjunctive therapy to stimulants for the treatment of attention deficit hyperactivity disorder in children and adolescents aged 6 to 17 years as part of a total treatment program.” View full resource at drugtopics.modernmedicine.com
Most Recently Shared on March 2, 2011 at 7:52 pm By:
FDA approves guanfacine ER tablets to treat ADHD in children, teens: FDA approved the use of once-daily gu... http://bit.ly/hRwbtM #adhd
FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets For Use As Adjunctive Therapy To Stimulants For The Treatment Of ADHD
medicalnewstoday.com — “Shire plc, (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) approved the use of once-daily INTUNIV® (gu” View full resource at medicalnewstoday.com
Most Recently Shared on March 1, 2011 at 8:33 pm By:
FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets For Use As Adjunctive Therapy To Stimulants F... http://bit.ly/ePyJtA #adhd
Medical News: APA: Guanfacine Helps as Add-On for ADHD - in Meeting Coverage, APA from MedPage Today
medpagetoday.com — “HONOLULU -- Whether given in the morning or at bedtime, extended-release guanfacine (Intuniv) added to stimulant medications for attention deficit-hyperactivity disorder (ADHD) in children and teens i” View full resource at medpagetoday.com
Most Recently Shared on May 20, 2011 at 8:46 pm By:
Thomas Loarie, Jr Health Advocate
@medpagetoday APA: Guanfacine Helps as Add-On for ADHD (CME/CE) http://bit.ly/mrn4ya #medical #Health
Shire Announces FDA Approval of Once-Daily Intuniv (guanfacine) Extended Release Tablets for the Treatment of ADHD in Children and Adolescents Aged 6 to 17
drugs.com — “Intuniv (guanfacine) is used to treat Attention-Deficit/Hyperactivity Disorder in children and adolescents aged 6 to 17 years. Includes Intuniv side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on September 4, 2009 at 12:32 am By:
FDA Approves Intuniv (guanfacine) for the Treatment of ADHD in Children and Adolescents - http://bit.ly/EObbC
APA: Guanfacine Helps as Add-On for ADHD (CME/CE) - QualityPoint Technologies
qualitypointtech.net — “HONOLULU (MedPage Today) -- Whether given in the morning or at bedtime, extended-release guanfacine (Intuniv) added to stimulant medications for attention deficit-hyperactivity disorder (ADHD) in children and teens improved symptom control, a researcher said here.” View full resource at qualitypointtech.net
Most Recently Shared on May 20, 2011 at 8:45 pm By:
APA: Guanfacine Helps as Add-On for ADHD (CME/CE): HONOLULU (MedPage Today) -- Whether given in the morning or at ... http://bit.ly/mORZse
Investigational Data Presented for INTUNIV (guanfacine) Extended-Release Tablets When Coadministered With Stimulants Showed ADHD Symptom Improvement in Overall, Morning and Evening Assessments - Drugs.com MedNews
drugs.com — “Shire plc (LSE SHP, Nasdaq SHPGY), the global specialty biopharmaceutical company, today presented research results of once-daily INTUNIV (guanfacine) Extended-” View full resource at drugs.com
Most Recently Shared on October 28, 2010 at 4:15 pm By:
Drugs and Devices OW OW Health
Investigational Data Presented for INTUNIV (guanfacine) Extended-Release Tablets When Coadministered With Sti... http://bit.ly/9aEmxf #drug
Study Data Show INTUNIV(TM) (guanfacine) Extended Release Tablets Co-administered With Stimulants Provided ADHD Symptom Improvement in Children and Adolescents - MarketWatch
marketwatch.com — “Study Data Show INTUNIV(TM) (guanfacine) Extended Release Tablets Co-administered With Stimulants Provided ADHD Symptom Improvement in Children and Adolescents - MarketWatch” View full resource at marketwatch.com
Most Recently Shared on May 21, 2010 at 3:43 pm By:
Peter H Brown Doctor and Psychologist
Study Data Show INTUNIV(TM) (guanfacine) Extended Release Tablets Co ... http://bit.ly/dliH5l #ADHD
FDA approves extended-release guanfacine (Intuniv®) as an adjunctive therapy to stimulants for the treatment of ADHD in children and adolescents - NeLM [2.1.9]
nelm.nhs.uk — “FDA approves extended-release guanfacine (Intuniv®) as an adjunctive therapy to stimulants for the treatment of ADHD in children and adolescents - NeLM [2.1.9]” View full resource at nelm.nhs.uk
Most Recently Shared on March 1, 2011 at 8:33 pm By:
FDA approves extended-release guanfacine (Intuniv®) as an adjunctive therapy to stimulants for the treatm... http://bit.ly/gF8pqX #adhd
Study Findings On ADHD Treatments Presented At Psychiatric Meeting
medicalnewstoday.com — “Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, has announced that it will present key scientific data on its Attention-Deficit/Hyperactivity Disorder (ADHD) t” View full resource at medicalnewstoday.com
Most Recently Shared on October 30, 2009 at 3:59 pm By:
MNT Psychology News Health News
Study Findings On ADHD Treatments Presented At Psychiatric Meeting: Shire plc (LSE: SHP, NASDAQ: SHPGY), the gl.. http://bit.ly/2g2hjD
Study Findings On ADHD Treatments Presented At Psychiatric Meeting
medicalnewstoday.com — “Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, has announced that it will present key scientific data on its Attention-Deficit/Hyperactivity Disorder (ADHD) t” View full resource at medicalnewstoday.com
Most Recently Shared on October 30, 2009 at 3:30 pm By:
psychiatryrounds Psychiatry and Support
Study Findings On ADHD Treatments Presented At Psychiatric Meeting: Shire plc (LSE: SHP, NASDAQ: SHPGY), the gl.. http://bit.ly/tDMfR
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
MPR
eMPR.com provides up-to-date, concise drug information at the point-of-care.
-
Peter H Brown
Peter H Brown Clinical Psychologist. I'm also a Husband & Dad & wannabe techno-junkie
-
Educator, Writer, Neuroscientist, Child and Adult psychiatrist, and is certified by the Nuclear Regulatory Commission for SPECT brain imaging. He specializes in advanced diagnostic and medical services for troubled children, adolescents and adults. His broad range of clinical experience from psychoanalysis to substance abuse, to psychopharmacology and SPECT neuroimaging, – and his experience with systems/functional medicine and biomedical assessments provides a comprehensive medical foundation for treatment interventions and recommendations. If you don't look, you can't see. At CorePsych mind/brain diagnosis evolves beyond the polemics of outdated categorical thinking driven by superficial labels. Virtual assessments available anywhere globally." />
Dr Charles Parker
Dr. Parker is an Educator, Writer, Neuroscientist, Child and Adult psychiatrist, and is certified by the Nuclear Regulatory Commission for SPECT brain imaging. He specializes in advanced diagnostic and medical services for troubled children, adolescents and adults. His broad range of clinical experience from psychoanalysis to substance abuse, to psychopharmacology and SPECT neuroimaging, – and his experience with systems/functional medicine and biomedical assessments provides a comprehensive medical foundation for treatment interventions and recommendations. If you don't look, you can't see. At CorePsych mind/brain diagnosis evolves beyond the polemics of outdated categorical thinking driven by superficial labels. Virtual assessments available anywhere globally.
Advertisement
